BCL2 and Thrombocytopenia: A dual inhibitor of Bcl2 and Bcl-XL, named Navitoclax (ABT-263), resulted to be cytotoxic in Bcl2-dependent neoplasia, but it induced excessive cell toxicity during clinical trials, resulting in thrombocytopenia, and thus limiting its clinical application [134].